6.94
price up icon1.31%   0.09
after-market Handel nachbörslich: 7.02 0.08 +1.15%
loading
Schlusskurs vom Vortag:
$6.85
Offen:
$6.91
24-Stunden-Volumen:
14,196
Relative Volume:
0.23
Marktkapitalisierung:
$77.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.66%
1M Leistung:
+4.99%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$6.85
$7.07
1-Wochen-Bereich:
Value
$6.32
$7.07
52-Wochen-Spanne:
Value
$5.70
$17.96

Imagenebio Inc Stock (IMA) Company Profile

Name
Firmenname
Imagenebio Inc
Name
Telefon
857-343-8292
Name
Adresse
12526 HIGH BLUFF DRIVE, SAN DIEGO
Name
Mitarbeiter
15
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
IMA's Discussions on Twitter

Vergleichen Sie IMA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMA
Imagenebio Inc
6.94 76.59M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.86 119.17B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
796.55 84.19B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
398.29 52.77B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
788.49 48.98B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
175.97 36.31B 447.02M -1.18B -906.14M -6.1812

Imagenebio Inc Stock (IMA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-11-25 Fortgesetzt Wedbush Underperform
2025-10-24 Eingeleitet Leerink Partners Outperform

Imagenebio Inc Aktie (IMA) Neueste Nachrichten

pulisher
Dec 31, 2025

Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st

Dec 31, 2025
pulisher
Dec 31, 2025

ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance

Dec 31, 2025
pulisher
Dec 29, 2025

Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks

Dec 29, 2025
pulisher
Dec 29, 2025

Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat

Dec 29, 2025
pulisher
Dec 21, 2025

ImageneBio chief medical officer resigns, transition planned - MSN

Dec 21, 2025
pulisher
Dec 18, 2025

ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks

Dec 18, 2025
pulisher
Dec 18, 2025

ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com

Dec 18, 2025
pulisher
Dec 14, 2025

ImageneBio assumed at Underperform from Neutral at Wedbush - MSN

Dec 14, 2025
pulisher
Dec 13, 2025

ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Dec 13, 2025
pulisher
Dec 13, 2025

ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World

Dec 13, 2025
pulisher
Dec 12, 2025

ImageneBio Extends Agreement with Miragene Inc. - MSN

Dec 12, 2025
pulisher
Dec 08, 2025

ImageneBio (IMA) price target decreased by 94.20% to 16.32 - MSN

Dec 08, 2025
pulisher
Dec 02, 2025

ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025
pulisher
Dec 01, 2025

ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Dec 01, 2025
pulisher
Nov 28, 2025

ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Nov 28, 2025
pulisher
Nov 28, 2025

Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat

Nov 28, 2025
pulisher
Nov 27, 2025

ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World

Nov 27, 2025
pulisher
Nov 27, 2025

ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World

Nov 27, 2025
pulisher
Nov 27, 2025

IMA interactive stock chart | ImageneBio, Inc. stock - Yahoo Finance Australia

Nov 27, 2025
pulisher
Nov 27, 2025

Price performance - Yahoo Finance Australia

Nov 27, 2025
pulisher
Nov 27, 2025

ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World

Nov 27, 2025
pulisher
Nov 27, 2025

ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World

Nov 27, 2025
pulisher
Nov 26, 2025

Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks

Nov 26, 2025
pulisher
Nov 25, 2025

Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa

Nov 25, 2025
pulisher
Nov 25, 2025

ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus

Nov 25, 2025
pulisher
Nov 25, 2025

Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India

Nov 25, 2025
pulisher
Nov 25, 2025

Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - marketscreener.com

Nov 25, 2025
pulisher
Nov 22, 2025

ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - MSN

Nov 22, 2025
pulisher
Nov 19, 2025

ImageneBio Highlights IMG-007 in Corporate Update - TipRanks

Nov 19, 2025
pulisher
Nov 19, 2025

ImageneBio, Inc Updates Corporate Presentation for Q4 2025 - TradingView

Nov 19, 2025
pulisher
Nov 17, 2025

FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World

Nov 17, 2025
pulisher
Nov 17, 2025

William Blair Estimates ImageneBio FY2025 Earnings - Defense World

Nov 17, 2025
pulisher
Nov 15, 2025

Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Yahoo Finance

Nov 15, 2025
pulisher
Nov 15, 2025

ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World

Nov 15, 2025
pulisher
Nov 12, 2025

[424B3] ImageneBio, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan

Nov 12, 2025
pulisher
Nov 12, 2025

ImageneBio Reports Third Quarter 2025 Financial Results - TradingView

Nov 12, 2025
pulisher
Nov 12, 2025

ImageneBio, Inc. SEC 10-Q Report - TradingView

Nov 12, 2025
pulisher
Nov 12, 2025

ImageneBio Reports Third Quarter 2025 Financial Results and - GlobeNewswire

Nov 12, 2025
pulisher
Nov 12, 2025

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - The Manila Times

Nov 12, 2025
pulisher
Nov 07, 2025

ImageneBio Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Nov 07, 2025
pulisher
Nov 06, 2025

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - The Manila Times

Nov 06, 2025
pulisher
Nov 05, 2025

ImageneBio Expands Board, Appoints New Audit Chair - TipRanks

Nov 05, 2025
pulisher
Nov 05, 2025

ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025 - MarketScreener

Nov 05, 2025
pulisher
Nov 02, 2025

ImageneBio initiated with an Outperform at Leerink - MSN

Nov 02, 2025
pulisher
Nov 01, 2025

ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update - Defense World

Nov 01, 2025
pulisher
Oct 29, 2025

Miragene Inc. Announces Extension of Key Service Agreement - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Imagenebio Inc elects not to renew agreement with MirageneSEC filing - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

ImageneBio IncOn Oct 23, Elects Not To Renew Agreement With MirageneSEC Filing - TradingView

Oct 29, 2025
pulisher
Oct 29, 2025

Imagenebio IncExtends Term for Miragene Se - 富途牛牛

Oct 29, 2025
pulisher
Oct 24, 2025

Leerink Partners initiates Imagene Bio stock with Outperform rating By Investing.com - Investing.com South Africa

Oct 24, 2025
pulisher
Oct 24, 2025

Leerink Partners initiates Imagene Bio stock with Outperform rating - Investing.com India

Oct 24, 2025

Finanzdaten der Imagenebio Inc-Aktie (IMA)

Es liegen keine Finanzdaten für Imagenebio Inc (IMA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$106.87
price up icon 0.90%
$34.26
price up icon 1.87%
$118.64
price up icon 10.48%
$99.85
price up icon 1.01%
biotechnology ONC
$337.89
price up icon 5.47%
$175.97
price up icon 3.35%
Kapitalisierung:     |  Volumen (24h):